21st October 2020 – Glucosenz hosted a Digital Health Innovations Webinar with some 50 attendees from Malaysia and four other countries. The webinar discussed the importance of Glucosenz in the medical world, along with future reverberations of the device and the positive effects it will impart on patients with diabetes.
The list of speakers were Dr. Hyzan Yusof, the Chief Executive Officer of Glucosenz, Dato’ Dr. Anuar Zaini, Professor of Internal Medicine for Jeffrey Cheah School of Medicine and Health Sciences, Angeline Chew Por Yan, Venture Capitalist and Director of Arris Venture Sdn. Bhd., and Jacob Thomas, who is the Digital Platform Lead of Glucosenz.
Glucosenz, an innovation developed through a joint effort with MIMOS Berhad, Malaysia's national applied research and development centre under the purview of the Ministry of Science, Technology and Innovation (MOSTI), is the world’s first non-invasive blood glucose monitoring device. Its goal is to meet the needs of diabetes patients and alleviate fears of pricking and discomfort when monitoring blood glucose level.
Currently, Glucosenz is on track to commercialisation, after favourable responses in meeting legal requirements. This signals a better future for diabetics where ease of access and practicality would make it easier for them to monitor their own glucose levels, avoiding complications related to the disease and improving their quality of life.
According to the National Health and Morbidity Survey (NHMS) 2019, an estimate of 1.7 million Malaysians are at risk of contracting diabetes, and the prevalence rate of diabetes in adults has increased from 13.4 percent in 2015 to 18.3 percent in 2019. Dr. Hyzan highlighted the desperate need of such a device to better improve the quality of life for diabetics. “Anyone, especially diabetic patients, can track their blood glucose levels and other health data in real-time using smartphone or web browser—anytime, anywhere,” he said.
Dato’ Dr. Anuar spoke at length on how glucose monitoring has always been at the back of physicians’ minds due to the complexity of monitoring one’s glucose level. While patients look for painless, affordable, continuous and real-time monitoring solutions, physicians want a reliable and accurate reading. “Glucosenz is ideal as it is non-invasive, easy to operate, cost effective, environmentally friendly and has artificial intelligence capability,” he said.
According to Jacob, the use of Artificial Intelligence in Glucosenz, with its AI Deep Learning capabilities enables a faster evolution and creation from a benchtop model to a portable and wearable device in the near future. Data collected will not only prove beneficial for physicians and patients’ care, but also open up more opportunities for Glucosenz.
Angeline shared that Glucosenz is now raising funds for commercialisation, and is currently in the phase of assembly preparation, with the official launch of Glucosenz portable version and commencement of research and development for a wearable version expected in 2023.